Efficacy and safety of the combined metabolic medication, containing inosine, nicotinamide, riboflavin and succinic acid, for the treatment of diabetic neuropathy: a multicenter randomized, double-blind, placebo-controlled parallel group clinical trial (CYLINDER).

BMJ Open Diabetes Res Care · 2022 · PMC9185393 · PMID 35680173

Europe PMC DOI

hedged sentence

0.3340

closest p · 6.7× alpha

0.3340

boldest claim

The sentences

did not reach statistical significancep=0.334not close (p > 0.1)

In the SINR group, there was also a trend to the decrease in the FPG levels (mmol/L) on day 29, day 57, and day 86 relative to the baseline level, but this trend did not reach statistical significance (p=0.334).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.